Search

Your search keyword '"Kardys, Isabella"' showing total 376 results
Start Over Author "Kardys, Isabella" Publication Year Range Last 3 years
376 results on '"Kardys, Isabella"'

5. Diagnostic Value of Aortic Valve Calcification Levels in the Assessment of Low-Gradient Aortic Stenosis

Author

Adrichem, Rik, Hokken, Thijmen W., Bouwmeester, Sjoerd, Abdelkarim, Ola, Vogel, Birgit, Blusztein, David I., Veulemans, Verena, Kuneman, Jurrien H., Geleijnse, Marcel L., Verhemel, Sarah, Van den Dorpel, Mark M.P., Kardys, Isabella, Tonino, Pim A.L., Chang, Su Min, Faza, Nadeen N., Jou, Stephanie, Ueyama, Hiroki A., Bartkowiak, Joanna, Zeus, Tobias, Bax, Jeroen J., Bertrand, Philippe B., Hahn, Rebecca T., Kodali, Susheel K., Lerakis, Stamatios, Mehran, Roxana, Little, Stephen H., Houthuizen, Patrick, and Van Mieghem, Nicolas M.

Published
2024
Full Text
View/download PDF

7. Trajectories of cardiac troponin in the decades before cardiovascular death: a longitudinal cohort study

Author

Kimenai, Dorien M., Anand, Atul, de Bakker, Marie, Shipley, Martin, Fujisawa, Takeshi, Lyngbakken, Magnus N., Hveem, Kristian, Omland, Torbjørn, Valencia-Hernández, Carlos A., Lindbohm, Joni V., Kivimaki, Mika, Singh-Manoux, Archana, Strachan, Fiona E., Shah, Anoop S. V., Kardys, Isabella, Boersma, Eric, Brunner, Eric J., and Mills, Nicholas L.

Published
2023
Full Text
View/download PDF

11. Targeted proteomics and metabolomics for biomarker discovery in abdominal aortic aneurysm and post-EVAR sac volume

Author

Vanmaele, Alexander, Bouwens, Elke, Hoeks, Sanne E, Kindt, Alida, Lamont, Lieke, Fioole, Bram, Moelker, Adriaan, ten Raa, Sander, Hussain, Burhan, Oliveira-Pinto, José, Ijpma, Arne S, van Lier, Felix, Akkerhuis, K. Martijn, Majoor-Krakauer, Danielle F, Hankemeier, Thomas, de Rijke, Yolanda, Verhagen, Hence JM, Boersma, Eric, and Kardys, Isabella

Published
2024
Full Text
View/download PDF

20. Vessel fractional flow reserve-based non-culprit lesion reclassification in patients with ST-segment elevation myocardial infarction: Impact on treatment strategy and clinical outcome (FAST STEMI I study)

Author

Groenland, Frederik T.W., Huang, Jager, Scoccia, Alessandra, Neleman, Tara, Ziedses Des Plantes, Annemieke C., Nuis, Rutger-Jan, den Dekker, Wijnand K., Wilschut, Jeroen M., Diletti, Roberto, Kardys, Isabella, Van Mieghem, Nicolas M., and Daemen, Joost

Published
2023
Full Text
View/download PDF

21. Aortic geometry and long-term outcome in patients with a repaired coarctation

Author

Minderhoud, Savine C S, primary, van Montfoort, Rick, additional, Meijs, Timion A, additional, Korteland, Suze-Anne, additional, Bruse, Jan L, additional, Kardys, Isabella, additional, Wentzel, Jolanda J, additional, Voskuil, Michiel, additional, Hirsch, Alexander, additional, Roos-Hesselink, Jolien W, additional, and van den Bosch, Annemien E, additional

Published
2024
Full Text
View/download PDF

22. Validation of Volume Calibration by Echocardiography for Invasive Ventricular Pressure Volume Studies in Transcatheter Valve Interventions

Author

van den Dorpel, Mark M.P., primary, van den Enden, Antoon J.M., additional, Verhemel, Sarah, additional, Adrichem, Rik, additional, Ren, Claire B., additional, Kardys, Isabella, additional, Nuis, Rutger-Jan, additional, Daemen, Joost, additional, Schreuder, Jan, additional, Geleijnse, Marcel L., additional, Hirsch, Alexander, additional, and Van Mieghem, Nicolas M., additional

Published
2024
Full Text
View/download PDF

24. Impact of membranous septum length on pacemaker need with different transcatheter aortic valve replacement systems: The INTERSECT registry

Author

Hokken, Thijmen W., Muhemin, Mohammed, Okuno, Taishi, Veulemans, Verena, Lopes, Bernardo B., Beneduce, Alessandro, Vittorio, Romano, Ooms, Joris F., Adrichem, Rik, Neleman, Tara, Kardys, Isabella, Daemen, Joost, Chieffo, Alaide, Montorfano, Matteo, Cavalcante, Joao, Zeus, Tobias, Pilgrim, Thomas, Toggweiler, Stefan, and Van Mieghem, Nicolas M.

Published
2022
Full Text
View/download PDF

28. The prognostic value of angiography-based vessel fractional flow reserve after percutaneous coronary intervention: The FAST Outcome study

Author

Neleman, Tara, Scoccia, Alessandra, Masdjedi, Kaneshka, Tomaniak, Mariusz, Ligthart, Jurgen M.R., Witberg, Karen T., Vermaire, Alise, Wolff, Quinten, Visser, Leon, Cummins, Paul, Kardys, Isabella, Wilschut, Jeroen, Diletti, Roberto, Den Dekker, Wijnand K., Zijlstra, Felix, Van Mieghem, Nicolas M., and Daemen, Joost

Published
2022
Full Text
View/download PDF

31. Proteomic biomarkers related to obesity in heart failure with reduced ejection fraction and their associations with outcome.

Author

Petersen, Teun B., Suthahar, Navin, Asselbergs, Folkert W., de Bakker, Marie, Akkerhuis, K. Martijn, Constantinescu, Alina A., van Ramshorst, Jan, Katsikis, Peter D., van der Spek, Peter J., Umans, Victor A., de Boer, Rudolf A., Boersma, Eric, Rizopoulos, Dimitris, and Kardys, Isabella

Subjects
PEPTIDES, NEURON development, HEART transplantation, CELL adhesion, HEART failure, HEART assist devices
Abstract

Objective: Heart failure (HF) pathophysiology in patients with obesity may be distinct. To study these features, we identified obesity‐related biomarkers from 4210 circulating proteins in patients with HF with reduced ejection fraction (HFrEF) and examined associations of these proteins with HF prognosis and biological mechanisms. Methods: In 373 patients with trimonthly blood sampling during a median follow‐up of 2.1 (25th–75th percentile: 1.1–2.6) years, we applied an aptamer‐based multiplex approach measuring 4210 proteins in baseline samples and the last two samples before study end. Associations between obesity (BMI > 30 kg/m2) and baseline protein levels were analyzed. Subsequently, associations of serially measured obesity‐related proteins with biological mechanisms and the primary endpoint (PEP; composite of cardiovascular mortality, HF hospitalization, left ventricular assist device implantation, and heart transplantation) were examined. Results: Obesity was identified in 26% (96/373) of patients. A total of 30% (112/373) experienced a PEP (with obesity: 26% [25/96] vs. without obesity: 31% [87/277]). A total of 141/4210 proteins were linked to obesity, reflecting mechanisms of neuron projection development, cell adhesion, and muscle cell migration. A total of 50/141 proteins were associated with the PEP, of which 12 proteins related to atherosclerosis or hypertrophy provided prognostic information beyond clinical characteristics, N‐terminal pro‐B‐type natriuretic peptide, and high‐sensitivity troponin T. Conclusions: Patients with HFrEF and obesity show distinct proteomic profiles compared to patients with HFrEF without obesity. Obesity‐related proteins are independently associated with HF outcome. These proteins carry potential to improve management of obesity‐related HF and could be leads for future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Abstract 12012: Subphenotypes of Heart Failure With Reduced Ejection Fraction Based on Repeated Measurements of 4210 Circulating Proteins Are Driven by Protein Subsets Reflecting Different Biological Mechanisms

Author

Petersen, Teun B, de Bakker, Marie, Asselbergs, Folkert W, Akkerhuis, K. Martijn, Brugts, Jasper J, van Ramshorst, Jan, Lumbers, Tom, Ostroff, Rachel, Katsikis, Peter D, van der Spek, Peter J, Umans, Victor A, Boersma, Eric, Rizopoulos, Dimitris, and Kardys, Isabella

Published
2022
Full Text
View/download PDF

35. Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk

Author

de Bakker, Marie, Scholte, Niels T.B., Oemrawsingh, Rohit M., Umans, Victor A., Kietselaer, Bas, Schotborgh, Carl, Ronner, Eelko, Lenderink, Timo, Aksoy, Ismail, van der Harst, Pim, Asselbergs, Folkert W., Maas, Arthur, Oude Ophuis, Anton J., Krenning, Boudewijn, de Winter, Robbert J., The, S. Hong Kie, Wardeh, Alexander J., Hermans, Walter, Cramer, G. Etienne, van Schaik, Ron H., de Rijke, Yolanda B., Akkerhuis, K. Martijn, Kardys, Isabella, Boersma, Eric, de Bakker, Marie, Scholte, Niels T.B., Oemrawsingh, Rohit M., Umans, Victor A., Kietselaer, Bas, Schotborgh, Carl, Ronner, Eelko, Lenderink, Timo, Aksoy, Ismail, van der Harst, Pim, Asselbergs, Folkert W., Maas, Arthur, Oude Ophuis, Anton J., Krenning, Boudewijn, de Winter, Robbert J., The, S. Hong Kie, Wardeh, Alexander J., Hermans, Walter, Cramer, G. Etienne, van Schaik, Ron H., de Rijke, Yolanda B., Akkerhuis, K. Martijn, Kardys, Isabella, and Boersma, Eric

Abstract

BACKGROUND: We aimed to identify patients with subphenotypes of postacute coronary syndrome (ACS) using repeated measurements of high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 in the year after the index admission, and to investigate their association with long-term mortality risk. METHODS AND RESULTS: BIOMArCS (BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome) was an observational study of patients with ACS, who underwent high-frequency blood sampling for 1 year. Biomarkers were measured in a median of 16 repeated samples per individual. Cluster analysis was performed to identify biomarker-based subphenotypes in 723 patients without a repeat ACS in the first year. Patients with a repeat ACS (N=36) were considered a separate cluster. Differences in all-cause death were evaluated using accelerated failure time models (median follow-up, 9.1 years; 141 deaths). Three biomarker-based clusters were identified: cluster 1 showed low and stable biomarker concentrations, cluster 2 had elevated concentrations that subsequently decreased, and cluster 3 showed persistently elevated concentrations. The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had a similar and favorable long-term mortality risk. Cluster 3 had the highest mortality risk. The adjusted survival time ratio was 0.64 (95% CI, 0.44-0.93; P=0.018) compared with cluster 1, and 0.71 (95% CI, 0.39-1.32; P=0.281) compared with patients with a repeat ACS. CONCLUSIONS: Patients with subphenotypes of post-ACS with different all-cause mortality risks during long-term follow-up can be identified on the basis of repeatedly measured cardiovascular biomarkers. Patients with persistently elevated biomarkers have the worst outcomes, regardless of whether they expe

Published
2024

36. Sex-specific cardiovascular protein levels and their link with clinical outcome in heart failure

Author

de Bakker, Marie, Loncq de Jong, Mylène, Petersen, Teun, de Lange, Iris, Akkerhuis, K. Martijn, Umans, Victor A., Rizopoulos, Dimitris, Boersma, Eric, Brugts, Jasper J., Kardys, Isabella, de Bakker, Marie, Loncq de Jong, Mylène, Petersen, Teun, de Lange, Iris, Akkerhuis, K. Martijn, Umans, Victor A., Rizopoulos, Dimitris, Boersma, Eric, Brugts, Jasper J., and Kardys, Isabella

Abstract

Aims: This study aims to provide insight into sex-specific cardiovascular protein profiles and their associations with adverse outcomes, which may contribute to a better understanding of heart failure (HF) pathophysiology and the optimal use of circulating proteins for prognostication in women and men. Methods and results: In 250 stable patients with HF with reduced ejection fraction (HFrEF), we performed trimonthly blood sampling (median follow-up: 26 [17–30] months). We selected all baseline samples and two samples closest to the primary endpoint (PEP; composite of cardiovascular death, heart transplantation, left ventricular assist device implantation, and HF hospitalization) or one sample closest to censoring and applied the Olink Cardiovascular III panel. We used linear regression to study sex-based differences in baseline levels and joint models to study differences in the prognostic value of serially measured proteins. In 66 women and 184 men (mean age of 66 and 67 years, respectively), 21% and 28% reached the PEP, respectively. Mean baseline levels of fatty acid-binding protein 4, secretoglobin family 3A member 2, paraoxonase 3, and trefoil factor 3 were higher in women (Pinteraction: 0.001, 0.007, 0.018, and 0.049, respectively), while matrix metalloproteinase-3, interleukin 1 receptor-like 1, and myoglobin were higher in men (Pinteraction: <0.001, 0.001, and 0.049, respectively), independent of clinical characteristics. No significant differences between sexes were observed in the longitudinal associations of proteins with the PEP. Only peptidoglycan recognition protein 1 showed a suggestive interaction with sex for the primary outcome (Pinteraction = 0.028), without multiple testing correction, and was more strongly associated with adverse outcome in women {hazard ratio [HR] 3.03 [95% confidence interval (CI), 1.42 to 6.68], P = 0.008} compared with men [HR 1.18 (95% CI, 0.84 to 1.66), P = 0.347]. Conclusions: Althou

Published
2024

37. Long term outcome after surgical ASD-closure at young age:Longitudinal follow-up up to 50 years after surgery

Author

Kauling, Robert M, Pelosi, Chiara, Cuypers, Judith A A E, van den Bosch, Annemien E, Hirsch, Alexander, Carvalho, João G, Bowen, Daniel J, Kardys, Isabella, Bogers, Ad J J C, Helbing, Wim A, Roos-Hesselink, Jolien W, Kauling, Robert M, Pelosi, Chiara, Cuypers, Judith A A E, van den Bosch, Annemien E, Hirsch, Alexander, Carvalho, João G, Bowen, Daniel J, Kardys, Isabella, Bogers, Ad J J C, Helbing, Wim A, and Roos-Hesselink, Jolien W

Abstract

OBJECTIVES: To describe the clinical outcome and quality of life up to 50 years after surgical atrial septal defect (ASD) closure at young age. Primary outcome is defined as MACE (all-cause mortality, cardiac re-interventions, ischemic stroke, endocarditis, heart failure and symptomatic arrhythmia).METHODS: Single-center, longitudinal cohort-study evaluating 135 consecutive patients who underwent ASD-closure before the age of 15 years between 1968 and 1980. Participants were invited for extensive cardiac evaluation and assessment of quality-of-life every 10 years.RESULTS: Eighty patients (86%) of 93 eligible survivors were included in this study (mean age 52 ± 5 years (range 41-63), 40% male). Median follow-up since surgery was 45 years (range 40-51). Cumulative survival after 50 years was 86% and comparable to the normal Dutch population. Cumulative event-free survival after 45 and 50-years was 59% and 46% respectively (re-intervention in 6, symptomatic arrhythmia in 25, and pacemaker implantation in 10 patients). Right ventricular ejection fraction on CMR was diminished in 6%. Exercise capacity was normal in 77%. There was no pulmonary hypertension. NT-proBNP was elevated in 61%. Quality of life was comparable with the general population. No predictors for late events were identified.CONCLUSION: Long-term survival after surgical ASD-closure in childhood is good and not statistically different at 50 years compared to the normal Dutch population. Re-intervention rate is low, there is no pulmonary hypertension. Right ventricular function was diminished in 6%, exercise capacity was good and stable over time with quality of life comparable to the general population. However, supraventricular tachycardia is common.

Published
2024

38. The different risk of new-onset, chronic, worsening, and advanced heart failure:A systematic review and meta-regression analysis

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., Brugts, Jasper J., Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all-cause mortality and HF hospitalizations associated with new-onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30-day and 1-year all-cause mortality, as well as 1-year HF hospitalization. Studies were pooled using random effects meta-analysis, and mixed-effects meta-regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30-day mortality rates did not reveal a significant distinction between hospital-admitted patients, with rates of 10.13% for new-onset HF and 8.11% for WHF (p = 0.10). However, the 1-year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new-onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta-analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF.

Published
2024

39. Aortic geometry and long-term outcome in patients with a repaired coarctation

Author

R&D Onderzoek, Team Medisch, Circulatory Health, Minderhoud, Savine C S, van Montfoort, Rick, Meijs, Timion A, Korteland, Suze-Anne, Bruse, Jan L, Kardys, Isabella, Wentzel, Jolanda J, Voskuil, Michiel, Hirsch, Alexander, Roos-Hesselink, Jolien W, van den Bosch, Annemien E, R&D Onderzoek, Team Medisch, Circulatory Health, Minderhoud, Savine C S, van Montfoort, Rick, Meijs, Timion A, Korteland, Suze-Anne, Bruse, Jan L, Kardys, Isabella, Wentzel, Jolanda J, Voskuil, Michiel, Hirsch, Alexander, Roos-Hesselink, Jolien W, and van den Bosch, Annemien E

Published
2024

40. Validation of Volume Calibration by Echocardiography for Invasive Ventricular Pressure Volume Studies in Transcatheter Valve Interventions

Author

van den Dorpel, Mark M.P., van den Enden, Antoon J.M., Verhemel, Sarah, Adrichem, Rik, Ren, Claire B., Kardys, Isabella, Nuis, Rutger-Jan, Daemen, Joost, Schreuder, Jan, Geleijnse, Marcel L., Hirsch, Alexander, Van Mieghem, Nicolas M., van den Dorpel, Mark M.P., van den Enden, Antoon J.M., Verhemel, Sarah, Adrichem, Rik, Ren, Claire B., Kardys, Isabella, Nuis, Rutger-Jan, Daemen, Joost, Schreuder, Jan, Geleijnse, Marcel L., Hirsch, Alexander, and Van Mieghem, Nicolas M.

Published
2024

41. Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum.

Author

Andrzejczyk, Karolina, Abou Kamar, Sabrina, van Ommen, Anne-Mar, Canto, Elisa Dal, Petersen, Teun B., Valstar, Gideon, Akkerhuis, K. Martijn, Cramer, Maarten Jan, Umans, Victor, Rutten, Frans H., Teske, Arco, Boersma, Eric, Menken, Roxana, van Dalen, Bas M., Hofstra, Leonard, Verhaar, Marianne, Brugts, Jasper, Asselbergs, Folkert, den Ruijter, Hester, and Kardys, Isabella

Subjects
VENTRICULAR ejection fraction, HEART failure, PROTEOMICS, CELL determination, CELLULAR control mechanisms
Abstract

Circulating proteins may provide insights into the varying biological mechanisms involved in heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). We aimed to identify specific proteomic patterns for HF, by comparing proteomic profiles across the ejection fraction spectrum. We investigated 4210 circulating proteins in 739 patients with normal (Stage A/Healthy) or elevated (Stage B) filling pressures, HFpEF, or ischemic HFrEF (iHFrEF). We found 2122 differentially expressed proteins between iHFrEF-Stage A/Healthy, 1462 between iHFrEF–HFpEF and 52 between HFpEF-Stage A/Healthy. Of these 52 proteins, 50 were also found in iHFrEF vs. Stage A/Healthy, leaving SLITRK6 and NELL2 expressed in lower levels only in HFpEF. Moreover, 108 proteins, linked to regulation of cell fate commitment, differed only between iHFrEF–HFpEF. Proteomics across the HF spectrum reveals overlap in differentially expressed proteins compared to stage A/Healthy. Multiple proteins are unique for distinguishing iHFrEF from HFpEF, supporting the capacity of proteomics to discern between these conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Long term outcome after surgical ASD-closure at young age: Longitudinal follow-up up to 50 years after surgery

Author

Kauling, Robert M., primary, Pelosi, Chiara, additional, Cuypers, Judith A.A.E., additional, van den Bosch, Annemien E., additional, Hirsch, Alexander, additional, Carvalho, João G., additional, Bowen, Daniel J., additional, Kardys, Isabella, additional, Bogers, Ad J.J.C., additional, Helbing, Wim A., additional, and Roos-Hesselink, Jolien W., additional

Published
2023
Full Text
View/download PDF

46. The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis.

Author

Shakoor, Abdul, Abou Kamar, Sabrina, Malgie, Jishnu, Kardys, Isabella, Schaap, Jeroen, de Boer, Rudolf A., van Mieghem, Nicolas M., van der Boon, Robert M.A., and Brugts, Jasper J.

Subjects
HEART failure, PROGNOSIS, MORTALITY, DEATH rate, SCIENTIFIC observation, CONFIDENCE intervals
Abstract

Aims: Heart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all‐cause mortality and HF hospitalizations associated with new‐onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF. Methods and results: We performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30‐day and 1‐year all‐cause mortality, as well as 1‐year HF hospitalization. Studies were pooled using random effects meta‐analysis, and mixed‐effects meta‐regression was used to compare the different HF groups. Among the 15 759 studies screened, 66 were included representing 862 046 HF patients. Pooled 30‐day mortality rates did not reveal a significant distinction between hospital‐admitted patients, with rates of 10.13% for new‐onset HF and 8.11% for WHF (p = 0.10). However, the 1‐year mortality risk differed and increased stepwise from CHF to advanced HF, with a rate of 8.47% (95% confidence interval [CI] 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new‐onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for advanced HF. Readmission rates for HF at 1 year followed a similar trend. Conclusions: Our meta‐analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards advanced HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Serial RV wall stress measurements: association with right ventricular function in repaired Tetralogy of Fallot patients

Author

Minderhoud, Savine C. S., primary, Hirsch, Alexander, additional, Marin, Francesca, additional, Kardys, Isabella, additional, Rodríguez-Matas, José F., additional, Chiastra, Claudio, additional, Roos-Hesselink, Jolien W., additional, Wentzel, Jolanda J., additional, Helbing, Willem A., additional, and Akyildiz, Ali C., additional

Published
2023
Full Text
View/download PDF

50. Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure

Author

de Bakker, Marie, primary, Petersen, Teun B, additional, Rueten-Budde, Anja J, additional, Akkerhuis, K Martijn, additional, Umans, Victor A, additional, Brugts, Jasper J, additional, Germans, Tjeerd, additional, Reinders, Marcel J T, additional, Katsikis, Peter D, additional, van der Spek, Peter J, additional, Ostroff, Rachel, additional, She, Ruicong, additional, Lanfear, David, additional, Asselbergs, Folkert W, additional, Boersma, Eric, additional, Rizopoulos, Dimitris, additional, and Kardys, Isabella, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results